Thymus, central T cell self-tolerance and type 1 diabetes by Geenen, Vincent
access to biological analysis for urinary albumin.
However, other screening methods such as the
Micral-Test II®, based on semiquantitative strip
assays, have been developed and proven useful
in screening for microalbuminuria. Unfortunate-
ly, Clinitek® Microalbumin has not been evalu-
ated against the earlier Micral-Test II® strips.
Furthermore, the decision to use a strip for
screening for microalbuminuria is dependent on
the cost of the strip and the cost of analysing
any positive samples using a biological assay.
Although the Clinitek® Microalbumin strip
appears to be a useful tool for screening for
microalbuminuria, further information is needed
before it can be utilized in local diabetes clinics.
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Summary
In the first paper, the authors characterized
individual cells synthesizing major type 1 dia-
betes-associated autoantigens such as
(pro)insulin, glutamic acid decarboxylase and
the tyrosine phosphatase-like protein IA-2 in the
human thymus and other lymphoid organs
(spleen, lymph nodes). Since these cells also
express CD83, CD11c, CD40, CD14, CD80,
CD86 and HLA class II, they may be qualified
as antigen-presenting cells, mainly dendritic
cells (DC) and macrophages. In addition, using
the TUNEL (terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end labelling)
method, apoptotic lymphocytes were identified
in close vicinity to these cells.
In the second paper, the same group describes
a differential splicing of the IA-2 mRNA
between the pancreas and lymphoid organs (thy-
mus and spleen). Pancreatic islets express full-
length mRNA and two alternatively spliced
transcripts. Thymus and spleen exclusively
express an alternatively spliced transcript lacking
exon 13. This exon of IA-2 encodes for trans-
membrane and juxtamembrane domains that
contain several target autoantigenic determi-
nants of type 1 diabetes. This finding identifies a
mechanism of gene expression that could play a
permissive role in the development of autoim-
munity through the absence of tolerance to IA-2
epitopes not expressed in lymphoid organs.
Comment
There is more and more evidence that the
intrathymic expression of tissue-specific self-anti-
gens plays a prominent role in the establishment
of immunological self-tolerance. In this regard,
these two papers lend further support to the con-
cept that the central immunological self-tolerance
of β-cell identity may be induced during thymic 
T cell differentiation [1].The thymus is a very
unique organ and constitutes the only site of per-
manent confrontation between the repertoire of
self-antigens presented by major histocompatibili-
ty complex (MHC) proteins and the diversity of
T cell receptors for antigen (TCRs) generated by
random recombination of gene segments encod-
ing a TCR variable part.The thymus is also the
major lymphoid organ located at the crossroads
between the immune and neuroendocrine sys-
tems. In this organ responsible for thymopoiesis
(T lymphocyte generation) [2], the neuro-
endocrine system regulates the process of T cell
differentiation from the very early stages. In 
addition, inside this organ, which is physically
separated from non-self-infectious antigens,
T lymphocytes undergo a complex educative
process that establishes the central T cell self-
tolerance of neuroendocrine principles [3, 4].
Contrary to common assumption, the thymus
functions throughout life and plays a fundamen-
tal role in the recovery of a repertoire of 
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competent T cells after intensive chemotherapy 
or during highly active antiretroviral therapy
[5–7].
From the first paper and a number of other
observations [1, 8–11], we may draw some
definitive conclusions on the intrathymic expres-
sion of insulin-related genes (INS, IGF1 and
IGF2). The members of this family are all
expressed in the thymus environment according
to a precise hierarchy and topography: IGF2
(thymic epithelial/nurse cells [TEC/TNC]) >
IGF1 (thymic macrophages) >> INS (thymic
DC). At the protein level, this hierarchical pat-
tern is of great importance since the tolerogenic
response primarily concerns the dominant epi-
topes of a protein family [12]. Contrary to
(pro)insulin, the blockade of thymic insulin-like
growth factor (IGF)-mediated signalling, at the
level of the IGF ligands (in particular IGF-II) or
IGF receptors, severely interferes with the early
stages of T cell differentiation [13].
In the second paper, a regulation in the estab-
lishment of immunological self-tolerance is sug-
gested by the very interesting observation of a dif-
ferential splicing of IA-2 mRNA between thymus 
and pancreas. Such a difference explains why
some important antigenic determinants derived
from IA-2 proteins are not tolerated and become
strongly autoantigenic. Such shaping of the self-
reactive T cell repertoire has already been shown
for a splice variant of a proteolipid self-protein
expressed in the murine thymic epithelium [14,
15].The preprotachykinin A gene (PPT-A) is also
transcribed by rat TEC, but thymus-specific
mRNA processing gives rise to only one of the
PPT-A-encoded peptides (neurokinin A) and not
the other (substance P) [16].With regard to the
neurohypophysial genes, oxytocin (OT) and vaso-
pressin (VP), both OT and VP transcripts are
detected in TEC/TNC from different species. At
the peptide level, however, thymic OT concentra-
tions are much higher than VP concentrations.
Consequently, more and more observations sug-
gest the existence of thymus-specific post-tran-
scriptional mechanisms [17].
Clinical and pharmacological implications
As already hypothesized by Burnet in 1973 [18],
the pathogenesis of autoimmune diseases could
form the appearance of ‘forbidden’ self-reactive
clones in the peripheral lymphocyte repertoire.
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Thymus physiology
❖ Negative selection of self-reactive T cells (> 95% of precursor T cells)
❖ Development of T cells self-tolerant and competent against non-self
IGF-II = thymic dominant self-antigen precursor of insulin family
Thymus pathophysiology
❖ Abnormal cytoarchitecture (NOD mice, BB rat, man)
❖ Absence of intrathymic transcription of IGF2
Selection and enrichment of T repertoire with ‘forbidden’ 
self-reactive T cells to the insulin family
Lymphopenia and regulatory T cell deficiency
❖ Role of environment (thymic innervation, steroids, virus?)
Molecular ‘bridge’ between self-reactive T cells and ß-cells
❖ Genetic susceptibility (role of MHC +++)






Fig. 1: Role of the thymus in the development of the autoimmune response against islet insulin-secreting β-cells.Together with
abnormalities of thymic cytoarchitecture, the thymus-specific defect of IGF2 expression is responsible both for lymphopenia (with
decreased regulatory T cells) and for the absence of central T cell self-tolerance of the insulin family.The influence of environmental
factors (such as enterovirus infection) could be exerted at the level of thymic T cell differentiation, as well as in the periphery through
the establishment of a bridge between the β-cell autoantigen and ‘forbidden’ self-reactive T cells. NOD, non-obese diabetic; BB, bio-
breeding. (Reprinted from [23] with permission from Bentham Science Publishers.)
Since the thymus is the primary site for induc-
tion of self-tolerance, thorough investigation of a
defective thymic censorship should provide the
scientific community with important keys to
understand the mechanisms underlying the
development of autoimmune responses. A num-
ber of abnormalities in thymic morphology and
cytoarchitecture have been described for several
autoimmune disorders. In accordance with this
hypothesis, INS transcripts were measured at
lower levels in the thymus of human fetuses with
short class-I VNTR (variable number of tandem
repeats) alleles, a genetic trait of type 1 diabetes
susceptibility [19, 20]. The expression of
insulin-related genes was also analysed in the
thymus, liver and brain of a common animal
model of type 1 diabetes, the biobreeding (BB)
rat. A thymus-specific defect of Igf2 expression
was evidenced in more than 80% of diabetes-
prone BB rats (BBDP) [21]. This defect
explains both the lymphopenia (including a lack
of antigen-specific regulatory/suppressive T cells
generated in the thymus [22]) and the absence
of central self-tolerance of insulin family in
BBDP rats. As a consequence of the defective
thymic censorship, self-reactive T cells bear-ing
TCRs oriented against dominant epitopes of
insulin-related peptides continuously migrate
from the thymus to the periphery with a poten-
tial cytotoxic power against the islet β-cells.
Under certain environmental influences, a mole-
cular ‘bridge’ could be installed between the tar-
get autoantigenic epitopes leading to activation
of such a self-reactive T cell pool and subse-
quent β-cell destruction (Fig. 1).
The investigation of neuroendocrine genes
expressed in the thymus has led to the identifi-
cation of neuroendocrine self-peptides. Through the
study of insulin-related gene expression in the
thymus, IGF-II — a prominent fetal growth fac-
tor — was identified as the dominant self-pep-
tide precursor of the insulin family expressed in
the thymus. This observation is in close accor-
dance with the theory of self-recognition which,
according to F.M. Burnet, is not an inherited
property but is gradually acquired in the course
of fetal life. Although the tolerogenic properties
of neuroendocrine self-peptides remain to be
further documented, they are strongly suspected
from what is known about the tolerance of clas-
sic hormones. The development of specific anti-
bodies by active immunization (or experimental-
ly induced breakdown of tolerance) revealed
that tolerance of IGF-II is higher than of IGF-I,
and much greater than tolerance of insulin.
Insulin is a primary autoantigen tackled by the
autoimmune response observed in type 1 dia-
betes and this could result from its very low 
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Fig. 2: Pharmacological perspectives: two opposing immune responses driven by two types of antigens.TREG, regulatory T cell.
expression in the thymus. Moreover, autoimmu-
nity has never been observed against IGF-II,
and the strong tolerance of this protein, linked
to its high expression in the thymus, can be con-
sidered as a consequence of the evolutive pres-
sure to protect a fundamental process such as
fetal development.
Thus, while insulin behaves as an immuno-
genic autoantigen of the insulin gene family,
IGF-II is the tolerogenic self-peptide precursor
of this family. It is now probably appropriate 
to establish a distinction between an autoanti-
gen and a self-antigen. According to this distinc-
tion, an autoantigen can be considered as an
‘altered’ self-antigen. Though they are highly
homologous, they are not absolutely identical
and this biochemical difference theoretically 
drives opposing immune responses (i.e.
immunogenic vs. tolerogenic responses) (Fig. 2).
The powerful tolerogenic properties of the thy-
mus should soon be exploited to cure and/or
prevent severe autoimmune diseases, such as
type 1 diabetes, which constitute the heavy toll
paid for the diversity and efficiency of the
immune system.
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